Current management of polycythemia vera

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


Over a century has elapsed since the first description of polycythemia vera (PV), and current treatment recommendations are primarily based on the results of clinical trials that were performed in the late 1960s and early 1970s. Continued identification and appropriate utilization of PV-specific biologic parameters may allow substantial modification of early diagnostic criteria. New cytoreductive treatment agents are increasingly being used without any evidence of superiority over conventional therapy. The role of aspirin is being readdressed by an ongoing controlled study. Transformation of PV into either myelofibrosis with myeloid metaplasia or acute leukemia remains a major complication that may not be influenced by current therapy.

Original languageEnglish (US)
Pages (from-to)1-7
Number of pages7
JournalLeukemia and Lymphoma
Issue number1
StatePublished - 2002


  • Anagrelide
  • Aspirin
  • Busulfan
  • Hydroxyurea
  • Interferon alfa
  • Pipobroman
  • Polycythemia

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Current management of polycythemia vera'. Together they form a unique fingerprint.

Cite this